ThinkSabio Latest News
Announces efficacy results from Phase 3 study in pediatrics (aged 6-17), for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment ADHD
LightDark
Announces efficacy results from Phase 3 study in pediatrics (aged 6-17), for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment ADHD